2-(4-溴苯基)-噁唑 | 176961-50-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-溴苯基)-噁唑
• 中文别名: 2-(4-溴苯基)-1,3-恶唑
• 英文名称: 2-(4-bromophenyl)oxazole
• 英文别名: 2-(4-bromophenyl)-1,3-oxazole；2-(4-Bromo-phenyl)-oxazole；2-(4-bromophenyl)-oxazole
• CAS: 176961-50-5
• 化学式: C₉H₆BrNO
• 分子量: 224.057
• InChiKey: LAPKDKRJQXERIR-UHFFFAOYSA-N

物化性质

• 沸点：
  296.6±42.0 °C(Predicted)
• 密度：
  1.524±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 储存条件：
  存储条件：2-8°C，密封，干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(4-bromophenyl)-1,3-oxazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(4-bromophenyl)-1,3-oxazole
CAS number: 176961-50-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6BrNO
Molecular weight: 224.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-溴苯基)-噁唑 在 盐酸 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 3.0h， 生成 N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide
  参考文献：
  名称：

  联苯磺酰胺内皮素受体拮抗剂。2.发现4'-恶唑基联苯磺酰胺是一类新型的高效，高选择性ET（A）拮抗剂。

  摘要：

  一系列作为内皮素-A的4'-恶唑基-N-（3,4-二甲基-5-异恶唑基）[1，1'-联苯] -2-磺酰胺衍生物的合成及构效关系（SAR）研究描述了（ET（A））受体拮抗剂。数据显示，当联苯磺酰胺的4'-位被恶唑环取代时，效力和代谢稳定性有了显着改善。酰基氨基甲基的其他2'取代进一步增加了结合活性，并提供了联苯磺酰胺系列中的第一个亚纳摩尔ET（A）选择性拮抗剂之一（17，ET（A）K（i）= 0.2 nM）。在所描述的化合物中，3（N-（3,4-二甲基-5-异恶唑基）-4'-（2-恶唑基）[1，1'-联苯基] -2-磺酰胺；

  DOI：

  10.1021/jm000105c
• 作为产物：
  描述：

  2-(4-溴苯基)-4,5-二氢噁唑 在 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 11.0h， 以88%的产率得到2-(4-溴苯基)-噁唑
  参考文献：
  名称：

  DDQ诱导杂环的脱氢对C ？C双键形成：2-噻唑和2-恶唑的合成

  摘要：

  像牛一样强： 2-噻唑和2-恶唑是通过2-噻唑啉和2-恶唑啉的氧化反应形成的，不需要在C4和C5位置处有取代基。DDQ在此转化过程中起氧化剂的作用，并且不需要金属。该通用步骤显示出良好的官能团耐受性，并以中等至极好的收率提供了各种2-噻唑和2-恶唑。

  DOI：

  10.1002/asia.201300267

文献信息

• [EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYCLOALKYLNITRILE PYRAZOLOPYRIDONES UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014146490A1

  公开（公告）日：2014-09-25

  Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  公式I的化合物被提供，这些化合物是JAK抑制剂，对于治疗JAK介导的疾病，如类风湿性关节炎、哮喘、慢性阻塞性肺病（COPD）和癌症等疾病是有用的。
• Benzoyl-piperazine derivatives
  申请人：Jolidon J. Synese

  公开号：US20050209241A1

  公开（公告）日：2005-09-22

  The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及具有以下通式的化合物 其中取代基如本文所述。这些化合物可用于治疗基于抑制甘氨酸摄取的疾病，如精神疾病、疼痛、记忆和学习方面的神经退行性功能障碍、精神分裂症、痴呆症以及认知过程受损的其他疾病，例如注意力缺陷障碍或阿尔茨海默病。
• [EN] NOVEL COMPOUNDS<br/>[FR] DERIVES DE DIAZEPINE 1-BENZOYLE SUBSTITUES EN TANT QU'AGONISTES DE RECEPTEUR D'HISTAMINE SELECTIVE H3
  申请人：GLAXO GROUP LTD

  公开号：WO2005040144A1

  公开（公告）日：2005-05-06

  The present invention relates to novel diazepanyl derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型二氮杂环庚基衍生物（I）的公式，其制备方法，含有它们的组合物以及它们在治疗神经和精神障碍中的用途。
• Azabicyclic heterocycles as cannabinoid receptor modulators
  申请人：Yu Guixue

  公开号：US20050143381A1

  公开（公告）日：2005-06-30

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R 1 , R 2 , R 3 , R 6 , R 7 , m and n are described herein.

  本申请描述了符合I式的化合物，包括至少一种符合I式的化合物和可选地一种或多种额外治疗剂的药物组合物，以及使用符合I式的化合物进行治疗的方法，包括单独使用和与一种或多种额外治疗剂结合使用。这些化合物的一般式I如下： 包括所有的前药、药用盐和立体异构体，R1、R2、R3、R6、R7、m和n如本文所述。
• Deaminative Reductive Cross-Electrophile Couplings of Alkylpyridinium Salts and Aryl Bromides
  作者：Jennie Liao、Corey H. Basch、Megan E. Hoerrner、Michael R. Talley、Brian P. Boscoe、Joseph W. Tucker、Michelle R. Garnsey、Mary P. Watson

  DOI：10.1021/acs.orglett.9b01014

  日期：2019.4.19

  A nickel-catalyzed reductive cross-coupling of alkylpyridinium salts and aryl bromides has been developed using Mn as the reductant. Both primary and secondary alkylpyridinium salts can be used, and high functional group and heterocycle tolerance is observed, including for protic groups. Mechanistic studies indicate the formation of an alkyl radical, and controlling its fate was key to the success

  使用锰作为还原剂，已经开发了烷基吡啶鎓盐和芳基溴化物的镍催化的还原交叉偶联。伯和仲烷基吡啶鎓盐都可以使用，并且观察到高官能团和杂环耐受性，包括对于质子基团。机理研究表明烷基的形成，控制其命运是该反应成功的关键。